VALUTAZIONE DELL'AGGREGAZIONE PIASTRINICA DI ALCUNI PARAMETRI EMOCOAGULATIVI E DEL PROFILO LIPIDICO IN PAZIENTI TRATTATI CON SULOCTIDIL

Translated title of the contribution: Evaluation of platelet aggregation, some blood clotting parameters, and the lipid profile in patients treated with Suloctidyl

G. Palmieri, M. Perego, I. M. Baldini

Research output: Contribution to journalArticlepeer-review

Abstract

A double-blind clinical trial (Suloctidyl versus placebo) was carried out to determine changes in platelet aggregation, anti-thrombin III, partial thromboplastin time, triglycerides, cholesterol, and HDL cholesterol induced by 300 mg/day active principle for 30 days in 40 patients with coronary, peripheral, and cerebral atherosclerosis and hyperlipoproteinaemia. The drug led to a decrease in platelet aggregation, and a positive change in the HDL:LDL (antiatherogen:atherogen) ratio, but did not alter antithrombin III or the partial thromboplastin time.

Translated title of the contributionEvaluation of platelet aggregation, some blood clotting parameters, and the lipid profile in patients treated with Suloctidyl
Original languageItalian
Pages (from-to)143-152
Number of pages10
JournalGazzetta Medica Italiana
Volume141
Issue number4
Publication statusPublished - 1982

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Evaluation of platelet aggregation, some blood clotting parameters, and the lipid profile in patients treated with Suloctidyl'. Together they form a unique fingerprint.

Cite this